NewAmsterdam Pharma
NAMS
131 hedge funds and large institutions have $2.11B invested in NewAmsterdam Pharma in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 30 reducing their positions, and 20 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 30
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
4% more funds holding
Funds holding: 126 → 131 (+5)
2.41% more ownership
Funds ownership: 101.24% → 103.65% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
8% less capital invested
Capital invested by funds: $2.28B → $2.11B (-$171M)
72% less call options, than puts
Call options by funds: $1.18M | Put options by funds: $4.16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$29M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$19.4M |
| 3 |
DM
Deerfield Management
New York
|
+$18.5M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
+$17.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$18.7M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$13.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$11.9M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$9.94M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.6M |
NAMS Hedge Fund Activity: Q2 2025 in Review
131 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q2 2025, worth a combined $2.11B — down 7.5% from $2.28B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new NAMS positions and 20 closed out — a net gain of 6 holders — while 58 added to existing stakes and 30 trimmed.
The largest buyer was Capital World Investors, adding an estimated $29M. The largest seller was Jennison Associates, cutting an estimated $18.7M.
- 131 institutional investors held NewAmsterdam Pharma (NAMS) as of Q2 2025, up from 126 in Q1 2025.
- Funds reported $2.11B of NewAmsterdam Pharma stock for Q2 2025, down 7.5% quarter-over-quarter.
- 26 funds opened new NewAmsterdam Pharma positions in Q2 2025 and 20 closed out, a net change of +6 holders.
- The largest NewAmsterdam Pharma buyer in Q2 2025 was Capital World Investors, an estimated $29M added.
- The largest NewAmsterdam Pharma seller in Q2 2025 was Jennison Associates, an estimated $18.7M sold.
Based on aggregated 13F filings for Q2 2025.